Mumbai-based pharma manufacturer of injectables (ampoules, vials, IV fluids), tablets/capsules and nutraceuticals, with CDMO contract manufacturing and exports to 25+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 9 | 10 | 10 | 12 | 12 | 12 | 12 |
| Reserves | -55 | -53 | -18 | -13 | 16 | 26 | 33 | 36 |
| Borrowings | 49 | 46 | 6 | 2 | 1 | 6 | 7 | 9 |
| Other Liabilities | 16 | 18 | 20 | 22 | 15 | 21 | 7 | 21 |
| Total Liabilities | 16 | 19 | 18 | 21 | 43 | 65 | 58 | 78 |
| AssetsFixed Assets | 8 | 8 | 7 | 8 | 10 | 21 | 21 | 23 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 5 |
| Other Assets | 8 | 12 | 11 | 13 | 33 | 41 | 33 | 51 |
| Total Assets | 16 | 19 | 18 | 21 | 43 | 65 | 58 | 78 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2 | -0 | 1 | 9 | 5 | -11 | -0 | -2 |
| Cash from Investing | 0 | -0 | -0 | -1 | -1 | -12 | -6 | -4 |
| Cash from Financing | -2 | 0 | -0 | -8 | -4 | 23 | 6 | 7 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 3 | -0 | 0 | 8 | 4 | -14 | -11 | -5 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (31.4×) and current (28.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 12% growth and a 29× exit, ₹150 only delivers your return if you pay ₹115. The price is currently baking in 17% growth.
EPS grows 12%/yr for 5 years, then fades to 6% over 2, exits at 29×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 12.0% | 5.81 |
| FY28 | 12.0% | 6.51 |
| FY29 | 12.0% | 7.29 |
| FY30 | 12.0% | 8.17 |
| FY31 | 12.0% | 9.15 |
| FY32 | 9.0% ·fade | 9.97 |
| FY33 | 6.0% ·fade | 10.57 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.